LB Pharmaceuticals Inc
LBRXBuild a strategy around LBRX
LB Pharmaceuticals Inc AI Insights
Informational only. Not investment advice.Snapshot
- Zero revenue pre-clinical biotech with 269.7M cash (84% of assets) and 23M annual burn - ~12 years runway at current rate[Cash and Equivalents]
- P/B of 0.37x values equity at 63% discount - market pricing high probability of R&D failure or dilution[Price to Book Ratio]
- 327.8M raised in stock issuance (TTM) vs 114.4M market cap - massive dilution already priced in[Issuance of Capital Stock]
Watch Triggers
- Research and Development TTM: Increase >50% from 8.6M baseline — Signals pipeline advancement into later-stage trials with higher costs
- Cash and Equivalents: Falls below 150M or burn rate exceeds 40M/year — Would compress runway to <4 years, triggering dilutive financing
- Issuance of Capital Stock: Any new equity raise announcement — Further dilution at 0.37x book destroys shareholder value
Bull Case
Trading at 37% of book value with 12-year runway - if any pipeline asset succeeds, current valuation is severely depressed
Negative enterprise value (-151.7M) means market assigns zero value to pipeline - any clinical progress is pure upside
Bear Case
Zero revenue with -6% ROE and no visibility on clinical milestones - value destruction until proof of concept
327.8M equity raise vs 114.4M market cap signals massive dilution; future raises likely if trials extend
Bull vs Bear Balance
AI-generated sentiment analysis based on fundamental metrics and market conditions.
Leverage LBRX's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.
Forward Thesis
Binary outcome: clinical success = 3-5x upside; failure = near-zero
- 8.6M R&D spend (TTM) indicates active pipeline progression
- 12+ year cash runway removes near-term financing risk
- 0.37x P/B provides margin of safety if assets liquidated
Valuation Context
Caveats
Public Strategies Rankings
See how LB Pharmaceuticals Inc ranks across different investment strategies.
Leverage LBRX's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.
LBRX Fundamentals
| Metric | Value | YoY Growth | Industry Percentile |
|---|---|---|---|
$137.97M | — | ||
$-128.11M | — | ||
0.00 | — | ||
$0 | — | ||
$-0.74 | — | ||
0% | — | ||
0% | — | ||
$-23.02M | — | ||
-6.06% | — | ||
Beta 5Y (Monthly) | unknown | — |
LBRX Dividend History
LBRX Stock Splits
LBRX SEC Filings
| Filing Date | Report Date | Report Type | Filing Link |
|---|---|---|---|
11/06/25 | 09/30/25 | 10-Q | |
06/30/25 | 06/30/25 | S-1 | |
09/12/25 | 06/30/25 | 424B4 | |
09/12/25 | 12/31/24 | 424B4 | |
11/06/25 | 09/30/24 | 10-Q | |
06/30/24 | 06/30/24 | Unknown | -- |
06/24/24 | 03/31/24 | DRS/A | |
06/24/24 | 03/31/23 | DRS/A |